Fate Therapeutics, Inc. (FATE)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.85-11.48%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · FATE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Clinical Development & Program Updates RECLAIM-LN, FT819 Phase 2 potentially registrational trial in lupus nephritis The Company continues to advance RECLAIM-LN, a Phase 2 potentially registrational…
Stated in 3 of 3 supplied quarters. Management reported: “Clinical Development & Program Updates RECLAIM-LN, FT819 Phase 2 potentially registrational trial in lupus nephritis The Company continues to advance RECLAIM-LN, a Phase 2 potentially registrational trial of FT819 in lupus nephritis (LN), with enrollment currently open across 17 active sites.” “"Dosing of the first patient in RECLAIM-LN, our Phase 2 potentially registrational trial, is an exciting milestone as we work to address significant unmet medical needs in patients with lupus nephritis using our FT819 off-the-shelf CAR T-cell treatment," said Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Clinical Development & Program Updates RECLAIM-LN, FT819 Phase 2 potentially registrational trial in lupus nephritis The Company continues to advance RECLAIM-LN, a Phase 2 potentially registrational…”
“"Dosing of the first patient in RECLAIM-LN, our Phase 2 potentially registrational trial, is an exciting milestone as we work to address significant unmet medical needs in patients with lupus nephrit…”
“"We are incredibly excited and focused on initiating RECLAIM-LN, our Phase 2 potentially registrational clinical trial of FT819 for the treatment of lupus nephritis to provide eligible trial patients…”
Third Quarter 2026 Financial Results • Cash & Investment Position: Cash, cash equivalents, and investments as of September 30, 2026, were $139.1 million, a quarterly decrease of $14.7 million.
Stated in 3 of 3 supplied quarters. Management reported: “Third Quarter 2026 Financial Results • Cash & Investment Position: Cash, cash equivalents, and investments as of September 30, 2026, were $139.1 million, a quarterly decrease of $14.7 million.” “Financial Guidance • Operating runway into 2028 driven by improvements to the expense structure of the organization, along with $153.8 million in cash, cash equivalents, and investments.”
“Third Quarter 2026 Financial Results • Cash & Investment Position: Cash, cash equivalents, and investments as of September 30, 2026, were $139.1 million, a quarterly decrease of $14.7 million.”
“Financial Guidance • Operating runway into 2028 driven by improvements to the expense structure of the organization, along with $153.8 million in cash, cash equivalents, and investments.”
“Financial Guidance • Operating runway into 2028, supported by $174.8 million in cash, cash equivalents, and investments.”
FT839: Next-generation off-the-shelf dual-CAR T-cell product candidate co-targeting CD19 and CD38 In July, the FDA cleared the Company’s IND application for FT839.
Stated in 3 of 3 supplied quarters. Management reported: “FT839: Next-generation off-the-shelf dual-CAR T-cell product candidate co-targeting CD19 and CD38 In July, the FDA cleared the Company’s IND application for FT839.” “In addition to FT819, our next generation CAR T-cell programs include FT839, a novel 13-point edited CAR T-cell product candidate co-targeting CD19 and CD38, which is advancing to first patient treatment in rheumatoid arthritis and other autoimmune diseases, as well as FT836, CAR T-cell product candidate targeting the stress ligands MICA/B for pan-tumor treatment which is showing early anti-tumor activity in colorectal cancer without conditioning chemotherapy.”
“FT839: Next-generation off-the-shelf dual-CAR T-cell product candidate co-targeting CD19 and CD38 In July, the FDA cleared the Company’s IND application for FT839.”
“In addition to FT819, our next generation CAR T-cell programs include FT839, a novel 13-point edited CAR T-cell product candidate co-targeting CD19 and CD38, which is advancing to first patient treat…”
“FT839: Next-generation Off-the-Shelf CAR T-cell Program Designed to co-target CD19 and CD38 and Armed with Novel Sword & Shield™ Technology Designed to Eliminate the Need for Conditioning Chemotherap…”
Progress FT819 through Phase 2 potentially registrational trial in lupus nephritis and expand clinical development in autoimmune diseases with outpatient, on-demand CAR T-cell therapy.
Sustain financial runway into 2028 by improving expense structure and managing cash, supported by cash, cash equivalents, and investments.
Over the trailing year it converted 0.83x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.